Zelinska, N.,
Iotova, V.,
Skorodok, J.,
Malievsky, O.,
Peterkova, V.,
Samsonova, L.,
Rosenfeld, Ron G.,
Zadik, Zvi,
Jaron-Mendelson, Michal,
Koren, Ronit,
Amitzi, Leanne,
Raduk, Dmitri,
Hershkovitz, Oren,
Hart, Gili (2017) and
children. The present trial was a safety and
dose-finding study for weekly MOD-4023 in
GHD children.
Design
Zelinska, N.,
Skorodokb, J.,
Malievsky, O.,
Rosenfeldd, Ron G.,
Zadike, Zvi,
Korenf, R.,
Vanderf, Sh.,
Hartf, G.,
Radziukg, K. (2016) -weekly subcutaneous (SC) administration of MOD-4023 were assessed in
children with
GHD over a period of 24 months
Deal, C,
Steelman, J,
Vlachopapadopoulou, E,
Stawerska, R,
Silverman, LA;,
Phillip, M,
Kim, HS,
Ko, CW,
Malievskiy, O,
Cara, JF,
Roland, CL,
Taylor, CT,
Valluri, SR,
Wajnrajch, MP,
Pastrak, A,
Miller, BS (2022) for once-weekly treatment of
children with
growth hormone deficiency (
GHD).
Objective: We aimed to compare
Chatelain, Pierre,
Malievskiy, Oleg,
Radziuk, Klaudziya,
Senatorova, Ganna,
Abdou, Magdy O.,
Vlachopapadopoulou, Elpis,
Skorodok, Yulia,
Peterkova, Valentina,
Leff, Jonathan A.,
Beckert, Michael (2017) -release human GH prodrug in development for
children with GH deficiency (
GHD).
Objective: To compare
Objective: To analyze the profile of sensitization to airborne allergens in
children with atopic
Шангареева, Р.Х.,
Мирасов, А.А.,
Глазырина, В.В.,
Тимербаева, Э.К.,
Shangareyeva, R.K.,
Mirasov, A.A.,
Glazyrina, V.V.,
Timerbaeva, E.K. (2017) AND METHODS: The study included 51
children. 40 (78.4%) of them had combined lesion of liver and other organs
Fuatovna, L.L.,
Khatimovna, K.D.,
Akhatovich, B.B.,
Labibovich, Y.V.,
Flaridovna, A.E.,
Yurievna, P.M. (2021) and hematopoietic apparatus in
children at the early stages of their formation, the risk factors for the development